Hematopoietic cell transplantation (HCT) has become the standard of care for numerous life-threatening illnesses. Here, we present a brief history of this evolving therapy, both worldwide and at City of Hope.
http://www.cityofhope.org/patient_care/treatments/HCT/history/Pages/default.aspx-------------------------------------------------------------------------
Department of Hematology & Hematopoietic Cell Transplantation
City of Hope was one of the first medical centers in the nation to perform a successful bone marrow transplant (BMT) for leukemia, in 1976.
Today, City of Hope leads the field of hematopoietic cell transplantation (HCT) as one of the world’s largest and most successful transplant centers with more than 9,300 transplants performed to date.We combine important research discoveries with superior clinical techniques to provide the most advanced treatments for leukemia, lymphoma, multiple myeloma, myelodysplasia and other blood disorders. City of Hope physicians are nationally recognized experts in the care of patients with these disorders.
We also provide new options for patients contemplating HCT – options which may make transplants possible for those who might not have previously been considered good transplant candidates.
These strengths have resulted in improved treatment outcomes, with longer disease-free survival, increased cure rates and fewer complications from treatment.
http://www.cityofhope.org/patient_care/treatments/HCT/Pages/default.aspx-------------------------------------------------------------------------
Lymphoma SPORE (Specialized Program of Research Excellence)
Stephen, J. Forman, M.D.
Principal Investigator
Andrew Raubitschek, M.D.
Co- Principal Investigator
The overall goal of the City of Hope Lymphoma Specialized Program of Research Excellence (SPORE) is to develop translational studies to improve the detection and therapy of Hodgkin’s and non-Hodgkin’s Lymphoma. This grant consists of four translational research projects and five cores developing novel approaches that are derived from molecular and immunologic studies of T-cell and antibody based therapies. An important theme of the translational studies in this grant is to develop lymphoma therapies that will reduce toxicities associated with current treatment regimens for Hodgkin’s and non-Hodgkin’s Lymphoma which can then be translated to the older patient population.
This Lymphoma SPORE also supports a Developmental Research Program and a Career Development Program to foster the advancement of pilot translational research projects and young investigators focused on lymphoma.
Read more about SPORE projects at City of Hope:
[Click here:Lymphoma SPORE]
